Stock Market Reviews

HOLX (Hologic, Inc.) News

Get the latest news, insights, and market updates on HOLX (Hologic, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Human Papilloma Virus (HPV) Test and Pap Smear/Test Market Research and Forecast Report 2025-2030, Competitive Analysis of Market leaders - Hologic, BD, Roche, QIAGEN, and Danaher
  The HPV testing and Pap test market is set to grow from USD 2.44 billion in 2025 to USD 3.94 billion by 2030, with a CAGR of 10.0%. This growth is fueled by increased awareness of cervical cancer and government-led screening initiatives. Consumables lead the market, driven by demand for reagents and collection kits essential for testing. While cervical cancer screening dominates, vaginal cancer screening is poised for rapid growth, aided by enhanced diagnostic capabilities. The Asia Pacific regi
  Nov 18, 2025 - $HOLX
• Should You Continue to Hold Hologic Stock Post Q4 Earnings?
  HOLX's solid Q4 growth and a pending $18.3B buyout sharpen its focus as the company prepares to end its publicly traded chapter.
  Nov 18, 2025 - $HOLX
• Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
  Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
  Nov 18, 2025 - $HOLX
• VolitionRX Ltd (VNRX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Revenue ...
  VolitionRX Ltd (VNRX) reports a 32% revenue increase and strategic agreements, while navigating market unpredictability and capital challenges.
  Nov 14, 2025 - $HOLX
• Hologic (HOLX): Exploring Current Valuation After Recent Share Price Momentum
  Hologic (HOLX) shares have edged slightly lower recently, moving down by about 0.4%. Despite this dip, the company’s performance over the past month has been positive, with stock returns climbing 13%. See our latest analysis for Hologic. Hologic’s stock has shown some encouraging momentum, with a 12.65% 1-month share price return standing out against a softer backdrop of longer-term performance. While its 1-year total shareholder return is down 4.2%, the recent rebound suggests investors are...
  Nov 14, 2025 - $HOLX
• Hologic Expands European Reach of Genius Digital Diagnostics System
  HOLX gains expanded CE marking for its Genius Digital Diagnostics System, enabling imaging of both cell and tissue specimens on one platform.
  Nov 13, 2025 - $HOLX
• VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
  VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter ended September 30, 2025. Volition management will host a conference call tomorrow, November 14 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.
  Nov 13, 2025 - $HOLX
• Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking
  MARLBOROUGH, Mass., November 12, 2025--Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking
  Nov 12, 2025 - $HOLX
• The transatlantic medtech investment gap: why does it exist and can it be plugged?
  Ivor Campbell, CEO of medtech recruitment consultancy Snedden Campbell, reflects on what companies in the UK and Europe can do to compete for investment against the US.
  Nov 11, 2025 - $HOLX
• 3 Low-Volatility Stocks Walking a Fine Line
  Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
  Nov 10, 2025 - $HOLX